Follow us...

 

Search News Archives

 

Special Offers and Promotions

 

 

News Channels

 

Laboratory Products

 

 

View Channel

News

 

 

View Channel

Microscopy | Image Analysis

 

 

View Channel

Separation Science

 

 

View Channel

Research & Case Studies

 

 

View Channel

Coronavirus (COVID-19)

 

 

View Channel

Brochures & Literature

 

 

View Channel

 

Conferences | Events

FDA EXCLUSIVE: A Spotlight on Regulation in Antibacterial Drug Development

publication date: Dec 15, 2016
 | 
author/source: SMi Group

smi

FDA Division of Anti-Infective Products Director, Sumathi Nambair, due to Present at Superbugs & Superdrugs 2017

SMi Group are thrilled to have industry expert Sumathi Nambair, provide regulatory and compliance updates on FDA legislation in antibacterial drug development at the 19th annual 2017 Superbugs & Superdrugs show, returning to Central London on 20th and 21st March.

The long running event will once again gather a global audience of scientific leaders, government bodies and anti-infective specialists, providing a focal point to discuss the global action plan on antimicrobial resistance.

In her current role at the FDA, Dr. Nambiar provides regulatory oversight for anti-infective products, including antibacterial, antifungal, and antiparasitic drugs. Her keynote presentation will explore FDA development programmes and activities to facilitate antibiotic drug discovery.

SMi Group are also delighted to welcome the expertise of Xavier Duportet, CEO from Eligo Bioscience who has recently confirmed to speak. Following a €2M deal from leading microbiome investor, Seventure, the talk will offer progressive insight into sequence-specific antimicrobials for targeted eradication of carriage.

The notable speaker line-up on at Superbugs & Superdrugs 2017 will also include:

  • Richard Bax, Senior Partner, TranScrip
  • Lloyd Czaplewski, Director, Chemical Biology Ventures
  • Chris Houchens, Branch Chief, BARDA
  • James Anderson, Head of Corporate Government Affairs, GlaxoSmithKline
  • Aileen Rubio, Head of Biology, Spero Therapeutics
  • David Williams, Chief Executive Officer, Discuva
  • Martin Everett, Chief Scientific Officer, ANTABIO SAS
  • Jean de Gunzburg, Scientific Director, Da Volterra
  • William J Weiss, Director, Pre-Clinical Services, UNT System College of Pharmacy

 


Find out more


About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk


 


 

Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

 

Popular this Month...

Our Top 10 most popular articles this month

 

Today's Picks...

 

 


 

Looking for a Supplier?

Search by company or by product

 


Company Name:

Product:


 

 

 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.


 

Media Partner